Eucrates Biomedical Acquisition Corp.
Status: Liquidated
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $104.80M |
|---|---|
| IPO Date | Oct 23, 2020 |
| CEO | Parag Saxena |
| Left Lead | Stifel Nicolaus |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 + 6 |
| IPO Sector |
Healthcare
Healthcare in North America and Europe |
| IPO Geography | US/Canada |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Oct 24, 2022 |
| Closing Date | Apr 26, 2023 |
EUCR
EUCRU
EUCRW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Eucrates Biomedical Acquisition Corp.:
- Structure and cap table
- 10 directors & officers
- 12 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Dr. Stelios Papadopoulos | 72 | Chairman |
| Parag Saxena | 65 | CEO and Director |
| Dr. Evangelos (Vangelis) Vergetis | 40 | President, COO and Director |
| Gonzalo Cordova | 65 | CFO |
| Shrikant Sathe | 65 | Senior VP |
| Atanuu Agarrwal | 31 | VP |
| Daphne Karydas | 47 | Director |
| William Campbell | 76 | Director |
| Nina Shapiro | 72 | Director |
| Amitabh (Amit) Singhal | 52 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Stifel Nicolaus | Joint BR | 7,000,000 | units |
| H.C. Wainwright | Joint BR | 3,000,000 | |
| 10,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 12 filings.